Eurazeo Healthcare

Eurazeo Healthcare is the dedicated healthcare investment franchise of Eurazeo, the listed Paris-based investment manager, deploying capital primarily through the Nov Santé vehicle to scale health infrastructure across Europe. The firm sits at the intersection of private equity and venture capital, with a structural preference for companies that have moved past pure venture risk into demonstrable commercial traction.

The thesis centers on health IT and healthcare software, medical devices and medtech, and biotech, with explicit emphasis on AI-enabled platforms within those categories. Nov Santé has invested in digital health infrastructure, telemedicine platforms, and localized pharmaceutical manufacturing, reflecting a European policy backdrop that has prioritized healthcare sovereignty since the pandemic. The healthcare-relevant portfolio strategy reads as a sovereign-flavored bet on digital and physical health infrastructure rather than a pure technology thesis.

Eurazeo Healthcare writes $5M to $25M checks and is active from Series A through Growth, with the bulk of activity sitting in the Series B and Growth bands where the firm’s PE heritage is most relevant. Geographic concentration is France and broader Europe, though Eurazeo’s platform supports cross-border execution and many portfolio companies operate across multiple European markets. Founders raising sub-$5M rounds should look elsewhere; this is not a seed vehicle.

The team draws on Eurazeo’s broader PE platform for value creation support, including operational improvement, M&A, and portfolio company governance, alongside healthcare-specific investment expertise. Specific partner names are not provided in the source data, and the LinkedIn listing for the healthcare-specific arm is unconfirmed, so founders should engage through Eurazeo’s main healthcare channels.

The approach is value-creation-led with PE rigor. Eurazeo Healthcare expects clear unit economics, credible paths to scale, and management teams capable of operating through the kind of professional governance that growth-stage and PE investors demand. The firm is a strong fit for European healthcare infrastructure companies that need patient capital and operational support to consolidate or scale across the continent. Founders looking for early venture risk capital or those building purely software-native models without infrastructure or services components may find better fits elsewhere.